Article Text

Download PDFPDF

Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
  1. B R Thanvi1,
  2. T C N Lo2
  1. 1Department of Integrated Medicine, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK
  2. 2Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK
  1. Correspondence to:
 Dr B R Thanvi
 Department of Integrated Medicine, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Infirmary Squire, Leicester LE1 5WW, UK; bthanvihotmail.com

Abstract

Levodopa is the most effective symptomatic treatment of Parkinson’s disease. However, after an initial period of dramatic benefit, several limitations become apparent including, “dopa resistant” motor symptoms (postural abnormalities, freezing episodes, speech impairment), “dopa resistant” non-motor signs (autonomic dysfunction, mood and cognitive impairment, etc), and/or drug related side effects (especially psychosis, motor fluctuations, and dyskinesias). Motor complications include fluctuations, dyskinesias, and dystonias. They can be very disabling and difficult to treat. Therefore, strategies should ideally be developed to prevent them. Though mechanisms underlying motor complications are only partially understood, recent work has revealed the importance of pulsatile stimulation of postsynaptic dopamine receptors and the disease severity. As a result of intermittent stimulation there occurs a cascade of changes in cell signalling leading to upregulation of the N-methyl-D-aspartate subtype of gamma-aminobutryric acid-ergic neurones. Modified preparations of levodopa (controlled release preparations, liquid levodopa), catecholamine-o-methyltransferase inhibitors, dopamine agonists, amantidine, and various neurosurgical approaches have been used in the prevention and/or treatment of motor complications. Current management of motor complications is less than satisfactory. With better understanding of the pathogenetic mechanisms, it is hoped that future therapeutic strategies will provide a safer and targeted treatment.

  • AADC, aromatic amino acid decarboxylase
  • COMT, catecholamine-o-methyltransferase
  • GABA, gamma-aminobutryric acid
  • MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • NMDA, N-methyl-D-aspartate
  • Parkinson’s disease
  • levodopa
  • dyskinesia
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.